SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Clinical trials for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New lupus drug PIT565 enters human safety trials
Disease control OngoingThis early-stage study tests a new drug called PIT565 in about 54 people with active lupus who have not gotten better with standard treatments. The main goal is to see if the drug is safe and how the body processes it. Participants will receive increasing doses of the drug and be…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
New lupus drug shows promise in Long-Term safety trial
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called litifilimab for people with active lupus. About 864 adults who finished earlier studies will continue taking the drug for up to 3 years, along with their usual treatments. The goal is to see how safe it is and how well it …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on lupus in tiny trial
Disease control OngoingThis Phase 2 trial is testing a new treatment called Descartes-08 for people with systemic lupus erythematosus (SLE). Descartes-08 uses a patient's own immune cells, modified to target a protein called BCMA, to try to control the disease. Only 6 participants with active lupus des…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new treatment called Prula-cel for people with autoimmune diseases like lupus, scleroderma, and vasculitis. Prula-cel uses donor immune cells engineered to target and destroy faulty immune cells that attack the body. The goal is to find a safe dose …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Adicet Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New lupus injection enters first human tests
Disease control OngoingThis early-stage trial tests a new drug called SG301, given as an injection under the skin every two weeks, for systemic lupus erythematosus (SLE). The study first gives a single dose to healthy volunteers to check safety, then gives multiple doses to people with lupus. The main …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Promising autoimmune therapy trial pulled before it even started
Disease control TerminatedThis study was designed to test a new treatment for people with autoimmune diseases like lupus, scleroderma, and myositis. It combined a specially engineered immune cell product (CLBR001) with a targeted antibody drug (SWI019), with or without a preparatory chemotherapy step. How…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New lupus drug candidate enters first human tests
Disease control OngoingThis early-stage study tests a new drug called KK4277 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to check safety and how the body processes the drug. It is too early to know if it works, but results will guide future research.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 19:13 UTC
-
Eye tests could spot silent vision damage in lupus patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study investigates whether people with systemic lupus erythematosus (SLE) show early signs of retinal damage before they notice any vision problems. Researchers will use advanced eye imaging and vision tests to compare lupus patients with healthy volunteers. The goal is to f…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: The First Affiliated Hospital of Anhui Medical University • Aim: Knowledge-focused
Last updated Jul 01, 2026 23:00 UTC
-
Can a blood test predict lupus flares? new study aims to find out
Knowledge-focused OngoingThis study follows 25 adults with inactive lupus to see if blood samples can predict when a flare will happen. Researchers will analyze genes and other molecules to find patterns linked to flare risk. The goal is to develop tools that help doctors personalize treatment and preven…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC